A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
NCT02623439
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
10
Enrollment
OTHER
Sponsor class
Stopped
Toxicity
Conditions
Hematologic Malignancies
Interventions
DRUG:
Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Sponsor
University of California, San Diego